速递｜减重最高31.3%，英矽智能提名口服GIPR拮抗剂ISM0676为临床前候选化合物

Core Viewpoint - The article discusses the development of ISM0676, an oral small molecule antagonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), by the biotech company InSilico Medicine. This compound is positioned as a potential complement to existing GLP-1 therapies for obesity and related metabolic diseases, aiming to improve weight loss efficiency, body composition maintenance, and long-term sustainability [5][8]. Group 1: Clinical Development - ISM0676 has shown significant weight management effects in preclinical studies, achieving a weight reduction of approximately 10.4% relative to baseline in a 27-day treatment cycle. When combined with semaglutide, the weight loss effect was amplified to 31.3%, while the control group experienced a weight increase of about 3% [5]. - The weight loss primarily resulted from a reduction in fat tissue, with muscle mass being relatively preserved, providing a foundational reference for future studies on body composition [5]. Group 2: Mechanism and Drug Properties - GIP plays a crucial role in regulating insulin secretion, fat storage, bone metabolism, and central appetite control, making it a key signaling node in metabolic networks. InSilico Medicine is exploring GIPR antagonism as a complementary mechanism to GLP-1 receptor agonists, targeting common issues in current weight loss therapies such as efficacy plateau, muscle loss, and weight rebound after discontinuation [8]. - Preclinical evaluations indicate that ISM0676 possesses good metabolic stability, low risk of drug interactions, and a relatively controllable safety window, showing certain advantages at clinically predicted dosage levels. These attributes provide a basis for further advancement in the competitive landscape of small molecule oral weight loss drugs, although it remains in the early validation stage [8]. Group 3: Research and Development Efficiency - The design and optimization of ISM0676 were supported by InSilico Medicine's generative AI platform, Chemistry42, completing the process from project initiation to clinical candidate nomination in about 14 months, with fewer than 200 synthesized and tested molecules [10]. - The company aims to validate the replicability of its AI-driven drug discovery system in the cardiovascular and metabolic fields. However, whether this efficiency advantage can translate into improved success rates in clinical stages remains to be seen [10]. Group 4: Pipeline and Strategic Direction - ISM0676 is part of InSilico Medicine's ongoing expansion in cardiovascular and metabolic disease research, which also includes explorations into obesity-related type 2 diabetes and potential cardiovascular complications such as obesity-related heart failure [10]. - Overall, InSilico Medicine is attempting to find differentiated pathways through multi-target, small molecule, and combination therapy strategies, beyond the GLP-1 dominated weight loss treatment landscape [10].